title: Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world.
abstract: Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardiovascular events, with assigned low density lipoprotein cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl and 115 mg/dl, respectively. Overall, the highest proportion of patients meeting their LDL-C target was seen in the UAE and Kuwait (49.5%), while the lowest was seen in Germany (14.3%). The smallest median distance to target was documented in Canada (18.8 mg/dl), and the largest in the Baltics (42.1 mg/dl). Interpretation and discussion of this data can be found in the manuscript entitled "Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients" (Gitt et al., 2016) [1].
authors.affiliation: Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany; Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
authors.forename: Anselm K
authors.initials: AK
authors.lastname: Gitt
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Dominik
authors.initials: D
authors.lastname: Lautsch
authors.affiliation: Toulouse University School of Medicine, Toulouse, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrieres
authors.affiliation: Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: John
authors.initials: J
authors.lastname: Kastelein
authors.affiliation: Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Drexel University College of Medicine, Philadelphia, PA, USA.
authors.forename: Heinz
authors.initials: H
authors.lastname: Drexel
authors.affiliation: Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Horack
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Brudi
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Brecht
authors.initials: B
authors.lastname: Vanneste
authors.affiliation: Institute for Pharmacology and Preventive Medicine, Mahlow, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Bramlage
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Francois
authors.initials: F
authors.lastname: Chazelle
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Vasilisa
authors.initials: V
authors.lastname: Sazonov
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Baishali
authors.initials: B
authors.lastname: Ambegaonkar
keywords: Global; Low-density lipoprotein cholesterol; Region; Statins; Treatment target